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A B S T R A C T
 
Cryptococcus spp. are common causes of mycoses in immunocompromised patients. To 
determine the drug susceptibilities of clinical Cryptococcus spp. isolates, the characteristics 
of 61 clinical Cryptococcus spp. complex isolates and their antifungal susceptibilities were 
investigated, including 52 C. neoformans and 9 C. gattii isolates collected at Shanghai between 
1993 and 2009. Antifungal susceptibility of clinical isolates to amphotericin B, fluconazole, 
itraconazole, and flucytosine were determined by the microdilution method M27-A2 and the 
ATB FUNGUS 3 kit. The 90% minimum inhibitory concentration (MIC90) and susceptibility 
ranges were as follows: 1 (0.0625-1) μg/mL for amphotericin B, 4 (0.125-16) μg/mL for 
ﬂuconazole, 0.25 (0.0313-4) μg/mL for itraconazole, and 4 (0.125-8) μg/mL for flucytosine. 
Fluconazole, itraconazole, and flucytosine have excellent in vitro activity against 
all tested clinical Cryptococcus spp., and we also found a high rate of tolerance to 
amphotericin B (MICs ranging from 0.55-1 μg/mL). Furthermore, C. neoformans isolates 
from acquired immune deficiency syndrome (AIDS) patients were less susceptible to 
fluconazole and flucytosine than those from non-AIDS patients. These data suggest 
that use of amphotericin B may lead to tolerance or resistance of the pathogen over 
time. There were also no significant associations between species, genotypes, and in vitro 
susceptibilities of these clinical isolates.
Infections by opportunistic pathogenic fungi, particularly 
Candida spp., Cryptococcus spp., and Aspergillus fumigatus, have 
become a serious medical problem in immunocompromised 
patients, who are highly susceptible to such infections. 
The Cryptococcus species complex consists of fatal fungal 
pathogens, which remain the most important cause of 
cryptococcal meningitis worldwide, in spite of the introduction 
of highly active antiretroviral treatment (HAART) to acquired 
immunodeficiency syndrome (AIDS) patients, in 1996.1
Cryptococcus neoformans and C. gattii are recognized within 
the Cryptococcus spp. complex, and they are closely related to 
basidiomycetous yeasts.2 C. neoformans contains C. neoformans 
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var. neoformans (serotype D), the hybrid isolates (serotype 
AD), and C. neoformans var. grubii (serotype A), which most 
commonly may cause meningoencephalitis, predominantly in 
immunocompromised hosts. C. gattii is divided into serotypes 
B and C, which are probable causes of cryptococcosis in 
immunocompetent hosts. Recently, PCR fingerprint patterns 
based on M13 or (GACA)4 primers have been used as the 
major genotyping technique in the ongoing global molecular 
epidemiologic survey of the Cryptococcus spp. complex, dividing 
over 600 clinical and environmental isolates into eight major 
molecular types: VNI (var. grubii, serotype A), VNII (var. 
grubii, serotype A), VNIII (serotype AD), VNIV (var. neoformans, 
serotype D), VGI, VGII, VGIII, and VGIV (C. gattii, serotypes B and C).3
Cryptococcosis is mainly found in AIDS patients worldwide, 
but in China it occurs most commonly in non-AIDS patients, 
and the proportion of non-AIDS patient cases were reportedly 
between 80.5-91.5%.4 The declining incidence of cryptococcosis 
in developed countries can be attributed to effective 
antiretroviral therapy.5 However, the rate of infection is still 
increasing in developing countries, especially in China, which is 
mainly caused by a growing immunocompromised population 
resulting from immunosuppressive therapies and AIDS. 
Several classes of antifungal drugs effectively treat 
cryptococcal infections, but the pathogen can develop 
resistance to these agents. In developed countries, many 
studies on the in vitro antifungal susceptibility of clinical strains 
of C. neoformans and C. gattii have been performed.6 Clinical 
isolates of Cryptococcus spp. were shown to remain highly 
susceptible (99%) to amphotericin B at a minimum inhibitory 
concentration (MIC) of ≤ 1 μg/mL, susceptible to flucytosine 
at a MIC of ≤ 4 μg/mL, susceptible to fluconazole at a MIC of 
≤ 8 μg/mL. Despite the apparent importance of drug resistance 
of clinical pathogens, its surveillance in developing countries is 
still poor or ignored in comparison with developed countries. 
In China, there have been few studies on the drug susceptibility 
of C. neoformans. Clinical isolates of C. neoformans from 
Taiwan were serotyped and their in vitro susceptibility 
to amphotericin B, fluconazole, and voriconazole were 
analysed.7 In 2004, Zhu et al. tested the 50% minimum 
inhibitory concentration (MIC50) of 81 C. neoformans isolates 
from mainland China: 4 (2-128) μg/mL for ﬂuconazole and 
0.03 (0.002-0.13) μg/mL for flucytosine, and estimated the 
fungicidal effects between different drug combinations.8
There have been some reports of resistant C. neoformans 
isolates that are not susceptible to amphotericin B, fluconazole, 
flucytosine, or itraconazole during treatment. The emergence 
of resistance to these antimycotic drugs suggests the need 
for vigilance and large-scale surveillance of the in vitro 
chemosensitivity of clinical strains. Therefore, it is important 
to obtain susceptibility data of various clinical isolates at 
different times. The current study aimed to evaluate the in 
vitro susceptibility of clinical isolates of C. neoformans and 
C. gattii from mainland Chinese against four commonly 
used antifungal drugs. We also sought to determine if there 
was any correlation between origin, genotypes, and in vitro 
susceptibility in Cryptococcus spp. complex isolates. 
A total of 61 clinical Cryptococcus species complex 
isolates were collected mainly from the southeast regions of 
mainland China, comprising Shanghai (n = 20), Guangdong 
(n = 12), Jiangsu (n = 9), Zhejiang (n = 5), Henan (n = 5), Anhui 
(n = 2), Jiangxi (n = 2), Fujian (n = 2), Sichuan (n = 2), Beijing 
(n = 1), Heilongjiang (n = 1), and these samples were recovered 
from the cerebrospinal fluid (n = 57), sputum (n = 2), feces 
(n = 1) and skin ulcer (n = 1). These clinical isolates were 
collected from patients with either cryptococcal meningitis or 
cryptococcal infection (one isolate per patient). All patients 
were admitted to our hospital between 1993 and 2009. Initial 
isolates were obtained at diagnosis. The majority was isolated 
from the cerebrospinal fluid. All isolates were identified by 
standard methods, including caffeic acid agar, positive urease 
test, or the API-20C AUX system (bioMérieux – France), and 
were maintained in frozen stock vials at –70°C. Each isolate 
was recovered at least twice from the frozen stock vials onto 
Sabouraud glucose agar (SDA) to ensure purity and viability, 
and a single colony was selected for analysis. The molecular 
type of the isolates was identified. The clinical Cryptococcus 
spp. were evaluated based on molecular characterization of 
genotype. The proportion of each genotype using the PCR 
fingerprint method was compared with previous Chinese 
report. Among the strains isolated, 52 strains of C. neoformans 
were assigned to VNI-III (45 of VNI, five of VNII and two of 
VNIII) and nine of C. gattii to VGI.
The in vitro activities of amphotericin B, itraconazole, 
fluconazole, and flucytosine were tested using the 
microdilution method M27-A2 (CLSI 2002).9 Standard antifungal 
powders of all tested drugs were obtained from Sigma (St. 
Louis, USA). Fluconazole and flucytosine were dissolved in 
sterile water; amphotericin B and itraconazole in dimethyl 
sulphoxide (DMSO); and before use, they were further diluted 
in RPMI 1640 medium (Sigma – St. Louis, USA) and buffered to 
a pH of 7.0 with morpholinepropanesulphonic acid (MOPS). 
The final concentrations of the different antifungal agents 
were 0.0313-16 μg/mL for amphotericin B and itraconazole, and 
0.125-64 μg/mL for fluconazole and flucytosine. Suspensions of 
yeast from 72-h cultures were prepared in sterile saline (0.85%) 
adjusted using a spectrophotometer reading at a 530 nm 
wavelength to a cell density of approximately 1-5 x 106 cfu/mL. 
This suspension was diluted at 1:50 followed by a 1:20 dilution 
in RPMI 1640 to obtain a final concentration of 1-5 x 103 cfu/mL. 
To perform in vitro susceptibility assays, 96-well plates 
were covered with 100 μL of different concentrations of the 
antifungal agents and added to 100 μL of the yeast suspension. 
The plates were incubated at 35°C for 72 h and the MIC values 
were determined. The end-point for amphotericin B MICs was 
defined as the 100% inhibition point compared to a growth 
control. End-points for azoles and 5-fluorocytosine (5FC) MICs 
were deﬁned as a prominent reduction of growth (≥ 50%) 
compared to a drug-free control well. Candida parapsilosis 
(ATCC 22019) and Candida krusei (ATCC 6258) were used for 
quality control in each assay to check the accuracy of drug 
dilutions and validity of the results.
The susceptibilities of all isolates were again determined by 
the ATB FUNGUS 3 kit (bioMérieux – France). Suspensions of 
yeast from 72-h cultures were prepared in sterile saline (0.85%) 
adjusted with a turbidity equivalent to 2 McFarland standard 
units, which is equivalent to an approximate cell density of 
1-5 x 106 cfu/mL. To perform the assay, 20 μL of the cell 
suspension was transferred into an ampule of ATB F2 medium 
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and 135 μL ATB F2 medium was dispensed into the ATB FUNGUS 
3 strips which consist of 16 pairs of cupules, of which 15 pairs 
contained five antifungal agents at several concentrations, and a 
positive growth control was included that was free of any agent. 
The five agents investigated were flucytosine, amphotericin B, 
fluconazole, itraconazole, and voriconazole. The concentrations of 
these agents were 4 and 16 μg/mL for flucytosine, 0.5-16 μg/mL for 
amphotericin B, 1-128 μg/mL for fluconazole and 0.125-4 μg/mL 
for itraconazole, and 0.06-8 μg/mL for voriconazole. These 
strips were incubated at 35°C for 72 h and the MICs read 
visually, according to the manufacturer’s instructions. 
Microdilution testing of four antifungal agents was 
performed using microdilution method M27-A2. The 
results obtained from the ATB FUNGUS 3 kit were similar to 
those obtained by the microdilution method. Table 1 shows MIC, 
MIC50, and MIC90 ranges of the four antifungals tested against 
61 Cryptococcus species complex isolates. Most Cryptococcus spp. 
showed uniform patterns of susceptibility to the four tested 
agents. When all strains were taken into consideration, they 
were susceptible to fluconazole, itraconazole, and flucytosine. 
The individual MIC ranges and MIC90 were 0.0313-4 μg/mL and 
0.25 μg/ml for itraconazole, 0.125-16 μg/mL and 4 μg/mL for 
fluconazole, 0.125-8 μg/mL and 4 μg/mL for flucytosine. 
The difference in MIC90 for fluconazole between AIDS 
and non-AIDS patients had been previously reported, but 
there were no data about the effect of flucytosine. When 
isolates were analyzed according to the origin of the patients 
(Table 1), 45 isolates from HIV-negative patients showed a 
lower geometric mean for fluconazole (1.1589/3.1228; p = 0.001) 
and flucytosine (1.4038/2.9720; p < 0.001), compared with the 
16 isolates from AIDS patients. Remarkably, there were no 
significant differences in susceptibility between the species 
for four agents (data not shown). 
Very few studies have compared the susceptibilities 
of C. neoformans and C. gattii among specific genotypes. 
The MICs for all isolates of each genotype against four agents 
are shown in Table 2. Although the geometric mean MICs were 
different, there was no statistically significant difference 
(p > 0.05) observed between genotypes VNI and VGI. 
The other genotypes, VNII and VNIII, were not compared 
because the number of isolates was too small. We found 
that within the VNI genotype group there were some isolates 
Isolates and antifungal agents MIC range (μg/mL) MIC50 (μg/mL) MIC90 (μg/mL) GM (μg/mL)
Non-AIDtS 45 isolates
 Amphotericin B 0.0625~1 0.5 1 0.5463
 Itraconazole 0.0313~0.5 0.125 0.25 0.1095
 Fluconazole 0.125~4 1 4 1.1589
 Flucytosine 0.125~4 2 4 1.4038
AIDS 16 isolates
 Amphotericin B 0.125~1 0.5 1 0.4310
 Itraconazole 0.0313~4 0.125 0.5 0.1683
 Fluconazole 0.5~16 4 8 3.1228
 Flucytosine 0.25~8 4 4 2.9720
Total (non-AIDS+AIDS)
 Amphotericin B 0.0625~1 0.5 1 0.5173
 Itraconazole 0.0313~4 0.125 0.25 0.1208
 Fluconazole 0.125~16 2 4 1.4550
 Flucytosine 0.125~8 2 4 1.6675
Significance was determined using the Student’s t-test (p < 0.05).
Table 1 - In vitro susceptibility of Cryptococcus spp. isolates to amphotericin B, itraconazole, fluconazole, and 
flucytosine according to origin


































VNI 0.0625~1 0.5 1 0.5156 0.0313~0.5 0.125 0.25 0.1122 0.125~16 2 4 1.3608 0.125~8 2 4 1.6371
VNII 0.25~1 0.5 1 0.4353 0.0625~4 0.25 4 0.2872 0.5~8 2 8 2.2974 0.25~2 2 2 1.1487
VNIII 0.125~1 0.5 1 0.3536 0.0625~0.25 0.0625 0.25 0.125 0.5~1 0.5 1 0.7071 4~4 4 4 4
VGI 0.125~1 1 1 0.6300 0.0313~0.5 0.125 0.5 0.1072 0.5~4 2 4 1.8517 0.5~4 2 4 1.8517
Table 2 - In vitro susceptibility of Cryptococcus spp. isolates to amphotericin B, itraconazole, fluconazole, and 
flucytosine according to genotypes
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from HIV-positive patients, while there were none from the 
VGI genotype group. To minimize interfering factors, we 
compared the VNI and VGI groups again, after removing 
the strains isolated from HIV-positive patients in VNI group, 
and still there was no significant difference (p > 0.05).
The lowest MIC50 and MIC90 (0.125/0.25 μg/mL) values were 
found for itraconazole, which were similar to the results of 
published studies from Asia, such as 0.032/0.125 μg/mL from 
India,10 0.125/0.5 μg/mL from Malaysia,11 except that there 
was one isolate with a MIC of 4 μg/mL for itraconazole.
The MIC values for fluconazole documented in our study 
were similar to those previously reported. One study from 
India showed that the MIC50 and MIC90 of fluconazole were 
4/16 μg/mL,10 which were also similar to another Malaysian 
study;11 two studies from Taiwan have shown that the MIC90 
of fluconazole were 2 and 8 μg/mL; while many other studies 
showed higher MIC values and increasing rates of resistance 
to fluconazole, such as one study from the mainland China 
with high MICs (2-128 μg/mL).12 
The MICs for flucytosine in our study were consistent 
with that of previous reports, but lower than some other 
studies. A study from Taiwan found a high MIC90 and 
susceptibility ranges of 16 (0.125-16) μg/mL. Compared with 
these Asian reports, our results found a lower MIC90 and sus-
ceptibility ranges of 4 (0.125-8) μg/mL; however, there was one 
study from Malaysia that showed a much lower value of 
MIC50 and MIC90 (0.023/0.25 μg/mL), which was compatible 
to one study presenting median MIC and susceptibility ranges 
0.06 (0.008-2) μg/mL from mainland China.
In previous evaluations of the effect of amphotericin B 
on Cryptococcus spp., most isolates appeared significantly 
susceptible to this agent.13 A study from Malaysia showed 
low MIC50 and MIC90 (0.25/0.38 μg/mL). A similar result was 
reported from Taiwan, where the MIC90 and susceptibility 
ranges were 0.5 (0.125-1) μg/mL, in agreement with results 
obtained by Chandenier et al.,14 who reported that both 
Asian and African isolates are susceptible to amphotericin 
B, whose MIC values did not exceed 0.125 μg/mL against the 
tested isolates. However, the results reported here show a 
slightly higher MIC than previous studies, with the MIC90 and 
susceptibility ranges of 1 (0.0625-1) μg/mL, respectively.
Our data are consistent with the results from the following 
report. A study from Brazil, using the time-kill method, showed 
that seven isolates (17.5% of all) were tolerant to amphotericin 
B (MICs ranged from 0.25-1 μg/mL) and correlated well with in 
vitro susceptibility and clinical response.15
Some studies have shown even higher MICs compared 
to our results, such as another study from Brazil displaying 
a high rate of resistance to amphotericin B (> 1 μg/mL), 
including 40% of C. gattii and 12% of C. neoformans isolates. 
Lozano-Chui et al.16 defined three isolates from 12 clinical 
strains as resistant to amphotericin B, with MICs of 
3.0-4.0 μg/mL that were subsequently found to be associated 
with therapeutic failure in the USA. Perkins et al.17 reported 
17 strains among Spanish clinical isolates (5.3% of all) that 
had MICs for amphotericin B of ≥ 2 μg/mL.
For these four agents, there were no significant differences 
in susceptibility between the species. This was consistent 
with the largest published series assessing species-specific 
MICs, which also showed no differences.18 However, other 
studies have described species-specific differences in 
antifungal susceptibility that may lead to higher rate of 
complications, slower response, and longer duration 
of treatment for patients with C. gattii infection. There was 
only one previous study about the correlation of genotypes 
and antifungal susceptibilities of C. gattii, and it found 
significant differences in MICs between some subtypes.19 
Amphotericin B deoxycholate has remained the mainstay 
of treatment for invasive fungal infections for many years20 
since it is active against a wide variety of fungi, including 
C. neoformans. Amphotericin B targets the ergosterol in the 
fungal plasma membrane to form a channel where the cell 
leaks potassium ions, resulting in a disruption of the proton 
gradient. In addition to this action, amphotericin B causes 
oxidative damage to the plasma membrane.
Although there are no breakpoints defined by the CLSI for 
amphotericin B and C. neoformans, it has been suggested an MIC 
value of 2 μg/mL is the resistance threshold for amphotericin 
B and the susceptibility pattern of C. neoformans strains is 
predictable, with MICs ranging from 0.12-0.5 μg/mL. Although 
our study did not identify any isolates with amphotericin 
B resistance, our data described elevated average MICs to 
amphotericin B, which was rarely observed in previous studies 
using Asian isolates. Unfortunately, very little was known 
about the clinical prognoses and outcomes of patients infected 
with these relatively high-MIC amphotericin B isolates. It was 
reported that treatment with amphotericin B may induce the 
development of clinical and in vitro amphotericin B resistance.21 
However, the reason for the low susceptibility to amphotericin 
B was not apparent in this study, and we suspect that the 
tolerant strains were isolated from patients that had likely been 
previously exposed to amphotericin B. These data suggest that 
the use of amphotericin B may lead to tolerance or resistance 
of the pathogen over time. We are currently gathering related 
clinical data to analyze the apparent cause of these tolerant 
strains and investigate the correlation between susceptibility 
results and clinical outcome.
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